Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Despite growing evidence affirming the therapeutic efficacy of ustekinumab (UST) in the treatment of Crohn’s disease (CD), optimizing clinical responses to this biologic continued to pose a significant challenge in clinical practice. From October 2020 to September 2024, a retrospective study was conducted on 114 patients with moderately-to-severely active CD who received optimized ustekinumab by 2 initial intravenous doses in three inflammatory bowel disease (IBD) centers.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
